Commercial Lilly falls on slower start for Foundayo versus Wegovy PharmaphorumSky-high expectations for sales of Eli Lilly's new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA.Metabolic & GLP-1Read full story pharminent April 27, 2026 (Last updated: April 27, 2026) Pharmaphorum Sky-high expectations for sales of Eli Lilly’s new oral GLP-1 agonist Foundayo have been dented by preliminary sales data from IQVIA. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: UK biotech could be bound for recovery, BIA report revealsNext: New NIHR-funded TRC for Parkinson’s disease Related Stories Commercial Kardigan targets IPO to support cardiology pipeline progression pharminent May 27, 2026 Commercial Lilly UK recruits ex-England cricketer as obesity champion pharminent May 15, 2026 Commercial A year after Vertex’s big launch, pain drug research faces a pivotal moment pharminent May 12, 2026
